GlassScriptPhysician profile
Judd Philip Bauer
NPI 1982833554
$3,476.12
in general payments reported to CMS, 2019-2025
21 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.26 · 2022: $30.54 · 2023: $2,270 · 2024: $313 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Food and Beverage: $1,294 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Food and Beverage | $1,294.48 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,132.96 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $232.67 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $180.45 | 2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $173.13 | 2023-2025 | |
| Amgen INC. | $117.63 | 2024-2025 | Tavneos, Krystexxa |
| Bard Peripheral Vascular, INC. | $114.71 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.02 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $68.27 | 2025 | |
| Calliditas Therapeutics US INC. | $52.59 | 2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $46.99 | 2023-2025 | Farxiga |
| Ardelyx, INC. | $39.78 | 2025 | Ibsrela |
| Vifor Pharma, INC. | $34.62 | 2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $33.01 | 2024-2025 | Jynarque |
| Inspire Medical Systems, INC. | $23.04 | 2025 | Inspire |
| Apellis Pharmaceuticals, INC. | $20.43 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $19.85 | 2024 | |
| Azurity Pharmaceuticals, INC. | $18.22 | 2024 | Horizant |
| Mozarc Medical US LLC | $17.25 | 2024 | Palindrome |
| Glaxosmithkline, LLC. | $17.24 | 2025 | Shingrix, Arexvy |
| Fresenius USA Marketing, INC. | $15.14 | 2025 | Velphoro |
| Abbott Laboratories | $15.12 | 2024 | Cardiomems |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judd Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.